These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12689410)

  • 1. Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.
    Núñez M; González-Requena D; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2003 Mar; 19(3):187-8. PubMed ID: 12689410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations.
    De Requena DG; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2005 Jun; 21(6):555-9. PubMed ID: 15989460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
    Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between nevirapine plasma concentrations and abnormal liver function tests.
    Almond LM; Boffito M; Hoggard PG; Bonora S; Raiteri R; Reynolds HE; Garazzino S; Sinicco A; Khoo SH; Back DJ; Di Perri G
    AIDS Res Hum Retroviruses; 2004 Jul; 20(7):716-22. PubMed ID: 15307917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
    Ena J; Amador C; Benito C; Fenoll V; Pasquau F
    Int J STD AIDS; 2003 Nov; 14(11):776-81. PubMed ID: 14624743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver toxicity caused by nevirapine.
    González de Requena D; Núñez M; Jiménez-Nácher I; Soriano V
    AIDS; 2002 Jan; 16(2):290-1. PubMed ID: 11807315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine.
    Martín-Carbonero L; Núñez M; González-Lahoz J; Soriano V
    HIV Clin Trials; 2003; 4(2):115-20. PubMed ID: 12671779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
    Manfredi R; Calza L; Chiodo F
    HIV Clin Trials; 2005; 6(6):302-11. PubMed ID: 16452064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
    Torti C; Costarelli S; De Silvestri A; Quiros-Roldan E; Lapadula G; Cologni G; Paraninfo G; Castelnuovo F; Puoti M; Carosi G;
    Drug Saf; 2007; 30(12):1161-9. PubMed ID: 18035868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine.
    Wongtrakul J; Thongtan T; Roytrakul S; Kumrapich B; Janphen K; Praparattanapan J; Supparatpinyo K; Smith DR
    Dis Markers; 2014; 2014():315824. PubMed ID: 25580050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients.
    Torti C; Lapadula G; Uccelli MC; Quiros-Roldan E; Regazzi M; Ladisa N; Micheli V; Orani A; Patroni A; Caputo SL; Tirelli V; Di Giambenedetto S; Cologni G; Costarelli S; Gargiulo F; Manca N; Carosi G;
    Int J Antimicrob Agents; 2007 Feb; 29(2):185-90. PubMed ID: 17011754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
    Manosuthi W; Chumpathat N; Chaovavanich A; Sungkanuparph S
    BMC Infect Dis; 2005 Aug; 5():67. PubMed ID: 16120209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
    Manosuthi W; Athichathanabadi C; Uttayamakul S; Phoorisri T; Sungkanuparph S
    BMC Infect Dis; 2007 Mar; 7():14. PubMed ID: 17352798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
    Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS
    AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assessment of nevirapine liver toxicity in patients with HIV and HVC coinfection].
    Rodríguez Guardado A; Maradona Hidalgo JA; Asensi Alvarez V; Cartón Sánchez JA
    Med Clin (Barc); 2004 Mar; 122(8):317. PubMed ID: 15030745
    [No Abstract]   [Full Text] [Related]  

  • 18. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.
    Dailly E; Billaud E; Reliquet V; Breurec S; Perré P; Léautez S; Jolliet P; Bourin M; Raffi F
    Eur J Clin Pharmacol; 2004 Jul; 60(5):343-8. PubMed ID: 15156302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
    Macías J; Castellano V; Merchante N; Palacios RB; Mira JA; Sáez C; García-García JA; Lozano F; Gómez-Mateos JM; Pineda JA
    AIDS; 2004 Mar; 18(5):767-74. PubMed ID: 15075511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.
    Giacomelli A; Riva A; Falvella FS; Oreni ML; Cattaneo D; Cheli S; Renisi G; Di Cristo V; Lupo A; Clementi E; Rusconi S; Galli M; Ridolfo AL
    BMC Infect Dis; 2018 Nov; 18(1):556. PubMed ID: 30419834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.